Associations of manganese superoxide dismutase genetic polymorphism with the susceptibilities of prostate, esophageal and lung cancers: A meta-analysis
10.3781/j.issn.1000-7431.2011.07.009
- Author:
Guo-Gui SUN
1
Author Information
1. Department of Radiotherapy
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Lung neoplams;
Meta-analysis;
Polymorphism, single nucleotide;
Prostatic neoplasms;
Superoxide dismutase
- From:
Tumor
2011;31(7):619-626
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the associations of manganese superoxide dismutase (MnSOD) genetic polymorphism with the susceptibilities of prostate, esophageal and lung cancers. Methods: Studies were identified by searching computerized databases (Cochrane Library, PubMed, etc.), accompanied by manual search. The case-control studies were selected according to defined inclusion and exclusion criteria. After quality evaluation and data abstraction, a meta-analysis was performed by using STATA 11.0 software. Results: A total of 22 case-control studies were eligible for this analysis, including 8 181 cases and 11 844 healthy controls. For prostate cancer, 12 case-control studies included 4 182 cases and 6 885 healthy controls. Meta-analysis showed that MnSOD polymorphism could significantly increase the risk of prostate cancer [heterozygote genotype: odds ratio (OR)=1.11, 95% confidence interval (CI)=1.01-1.22; homozygote genotype: OR=1.25, 95%CI=1.03-1.51); dominant genotype: OR=1.15, 95%CI=1.01-1.31)]. For esophageal cancer, 4 case-control studies contained 620 cases and 909 healthy controls. Meta-analysis showed that MnSOD polymorphism could significantly increase the risk of esophageal cancer [heterozygote genotype: OR=1.58, 95%CI=1.22-2.04; homozygote genotype: OR=2.25, 95%CI=1.61-3.15); recessive genotype: OR=1.69, 95%CI=1.07-2.67); dominant genotype: OR=1.74, 95%CI=1.36-2.22)]. For lung cancer, 6 case-control studies contained 3 375 cases and 4 050 healthy controls. Meta-analysis showed that MnSOD polymorphism could significantly decrease the risk of lung cancer [homozygote genotype: OR=0.68, 95%CI=0.59-0.78); recessive genotype: OR=0.71, 95%CI=0.54-0.93); dominant genotype: OR=0.83, 95%CI=0.75-0.92)]. Conclusion: MnSOD polymorphism is associated with elevated risks of prostate and esophageal cancers, but decreased risk of lung cancer. Copyright© 2011 by Tumor.
